Table 2.

Recommended monitoring during hGH therapy in adults with PWS [46].

Anthropometrics	Every 3–6 months Weight BMI
	Every 6–12 months Waist circumference Skin fold thickness if possible
Endocrine Monitoring	IGF-1: annually and as indicated for dose titration
	Thyroid function: within 3–6 months and at least annually
Metabolic Monitoring	Annually Hemoglobin A1c Fasting glucose and insulin OGTT if high risk
Obesity Related Monitoring	Annually Blood pressure Fasting lipids Consider AST and ALT
Side Effects	Assess for lower extremity edema at every follow up visit
	Clinically screen for signs/symptoms of sleep apnea
Benefits of Therapy	Body composition assessment every 2 years
	Cognitive status evaluation: consider on individual basis
	Motor function evaluation: consider on individual basis